Lu (Maggie) Qian: How Adaptive Trial Design Reveals Treatment Effects in COVID-19
Lu (Maggie) Qian, Founder at Zetyra, Creator and Editor at Evidence in the Wild, shared a post on LinkedIn:
”Four randomized controlled trials of IL-6 receptor antagonists in COVID-19 showed no significant benefit.
Then Remap-cap reported that tocilizumab and sarilumab both worked, with >99.9% posterior probability of superiority and confirmed survival benefit at six months.
The difference wasn’t the drug. It was the design.
Remap-cap used a multifactorial platform design.
Patients were randomized across multiple domains simultaneously, corticosteroids, IL-6 antagonists, anticoagulation, antivirals, convalescent plasma, and a Bayesian model learned which components worked, and for whom, across all domains at once.
Earlier trials enrolled less severely ill patients.
Remap-cap enrolled ICU patients.
It allowed concurrent dexamethasone.
And it had the statistical machinery to isolate the IL-6 effect on top of steroids.
It detected what single-question trials could not.
Then the same platform revealed a different vulnerability.
While the corticosteroid domain was randomizing hydrocortisone vs. no hydrocortisone, the recovery trial announced that dexamethasone reduced mortality.
Overnight, 93% of patients were receiving corticosteroids as background therapy regardless of randomization.
The adaptive engine worked as designed. It just didn’t work fast enough.
A simple, large trial answered the question before the more sophisticated Bayesian platform could.
No amount of pre-specification can fully anticipate the information environment a trial will encounter.
Meanwhile, most Phase III trials use covariate-adaptive randomization, and then analyze the data as though they used simple randomization, leaving power on the table.
Corrected inference methods exist.
The carat R package implements them.
Most practicing biostatisticians haven’t heard of it.
Randomization determines what a trial can learn, not just who gets what treatment.
It should be one of the first design decisions.
Not the last.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question